Compare GP & SHPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GP | SHPH |
|---|---|---|
| Founded | 2010 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4M | 5.2M |
| IPO Year | 2013 | 2022 |
| Metric | GP | SHPH |
|---|---|---|
| Price | $0.96 | $1.00 |
| Analyst Decision | Hold | |
| Analyst Count | 1 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 12.5K | ★ 191.2K |
| Earning Date | 02-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.23 | $0.12 |
| 52 Week High | $4.00 | $5.59 |
| Indicator | GP | SHPH |
|---|---|---|
| Relative Strength Index (RSI) | 43.80 | 56.23 |
| Support Level | $0.87 | $0.80 |
| Resistance Level | $1.15 | $1.06 |
| Average True Range (ATR) | 0.05 | 0.10 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 45.19 | 61.57 |
GreenPower Motor Co Inc is the manufacturer and distributor of all-electric charter, school, and city buses. The company offers electric-powered transit buses deploying electric drive and battery technologies with a lightweight chassis and low-floor body. Its product line includes all-electric transit buses, all-electric school buses, and shuttle buses. The company's buses depend on clean sheet design and utilize a custom battery management system and a proprietary flex power system for the drive motors. Geographically, the company generates a majority of its revenue from the United States of America and the rest from Canada.
Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company has one operating segment with a focus on the development of novel drug therapies, including cancer therapies, extending new applications of radiation therapy, and other drug development, including through the use of the Molecule.ai platform by the company as well as licensing the right to use Molecuile.ai to others. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. Its pipeline includes: Ropidoxuridine, HDAC Inhibitors, PSMA-B, and PC-Rad Test.